MX2021001672A - Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. - Google Patents

Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.

Info

Publication number
MX2021001672A
MX2021001672A MX2021001672A MX2021001672A MX2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequence
sequence number
sequence represented
cell
Prior art date
Application number
MX2021001672A
Other languages
English (en)
Inventor
Young Ho Kim
Byoung Se Kwon
Kwang Hee Kim
Ji Won Chung
Young Gyoon Chang
Bo Rim Yi
Jung Yun Lee
Seung Hyun Lee
Sun Woo Im
Jin Kyung Choi
Hyun Tae Son
Eun Hye Yoo
Original Assignee
Eutilex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutilex Co Ltd filed Critical Eutilex Co Ltd
Publication of MX2021001672A publication Critical patent/MX2021001672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención se refiere a una molécula de unión a antígeno que comprende una región variable de cadena pesada que comprende una región determinante de la complementariedad 1 de cadena pesada (HCDR1) que comprende una secuencia de aminoácidos representada por la Secuencia N.º 1, una HCDR2 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 2 y una HCDR3 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 3; una región variable de cadena ligera que comprende una región determinante de la complementariedad 1 de cadena ligera (LCDR1) que comprende una secuencia de aminoácidos representada por la Secuencia N.º 4, una LCDR2 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 5 y una LCDR3 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 6; en donde la molécula de unión a antígeno es un receptor de linfocitos T (TCR); y a una línea de células que expresa el mismo.
MX2021001672A 2018-08-10 2019-08-12 Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. MX2021001672A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717267P 2018-08-10 2018-08-10
US201962867503P 2019-06-27 2019-06-27
PCT/KR2019/010244 WO2020032784A1 (ko) 2018-08-10 2019-08-12 Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포

Publications (1)

Publication Number Publication Date
MX2021001672A true MX2021001672A (es) 2021-07-15

Family

ID=69414238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001672A MX2021001672A (es) 2018-08-10 2019-08-12 Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.

Country Status (11)

Country Link
US (2) US11013765B2 (es)
EP (1) EP3835320A4 (es)
JP (1) JP2021533755A (es)
KR (1) KR20210043623A (es)
CN (1) CN113366017A (es)
AU (1) AU2019317229A1 (es)
BR (1) BR112021002487A2 (es)
CA (1) CA3109209A1 (es)
MX (1) MX2021001672A (es)
SG (1) SG11202101169PA (es)
WO (1) WO2020032784A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
MX2021001672A (es) * 2018-08-10 2021-07-15 Eutilex Co Ltd Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
US20220010332A1 (en) * 2020-07-08 2022-01-13 Neuracle Genetics Inc. Intron fragments
KR20220122831A (ko) * 2021-02-26 2022-09-05 주식회사 이뮤노로지컬디자이닝랩 HLA class II에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2022220648A1 (ko) * 2021-04-15 2022-10-20 주식회사 유틸렉스 Hla-dr 특이적 키메라 항원 수용체 및 이의 용도
CA3223720A1 (en) * 2021-06-30 2023-01-05 Neville E. SANJANA Methods and compositions for improved immunotherapies
WO2023076883A1 (en) * 2021-10-27 2023-05-04 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023325A (en) 1911-10-21 1912-04-16 Frank B Miller Poultry-feeder.
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1988001630A1 (en) 1986-09-04 1988-03-10 Nikkiso Co., Ltd. Whisker-reinforced composite material
DE3852074D1 (de) 1987-03-20 1994-12-15 Creative Biomolecules Inc Verfahren zur reinigung von rekombinanten polypeptiden.
AU601273B2 (en) 1987-03-20 1990-09-06 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
KR100701923B1 (ko) 2006-03-15 2007-03-30 주식회사 녹십자 항- ｂ림프종 단일클론항체 및 이를 생산하는 하이브리도마세포주
CN102250245B (zh) * 2010-05-27 2014-05-14 四川大学 抗b细胞淋巴瘤的双特异性抗体及其用途
GB2481983A (en) 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
CN108103085A (zh) 2010-12-09 2018-06-01 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
CA3209571A1 (en) * 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
LT2872171T (lt) * 2012-07-13 2021-04-26 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo reguliavimas
CA2901960C (en) 2013-02-20 2022-10-04 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
KR101605421B1 (ko) * 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
EP3766895A1 (en) 2014-12-03 2021-01-20 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
KR20230146100A (ko) 2014-12-12 2023-10-18 2세븐티 바이오, 인코포레이티드 Bcma 키메릭 항원 수용체
CN107847601A (zh) * 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US20180355014A1 (en) 2015-12-03 2018-12-13 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
CN110225766A (zh) 2016-09-23 2019-09-10 南加利福尼亚大学 嵌合抗原受体和组合物及其使用方法
EP3568469A4 (en) 2017-02-21 2020-11-11 Eutilex Co., Ltd. HLA-DR-CART COMPOSITIONS AND METHOD OF MANUFACTURING AND USING THEREOF
MX2021001672A (es) 2018-08-10 2021-07-15 Eutilex Co Ltd Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.

Also Published As

Publication number Publication date
KR20210043623A (ko) 2021-04-21
SG11202101169PA (en) 2021-03-30
CA3109209A1 (en) 2020-02-13
BR112021002487A2 (pt) 2021-07-27
JP2021533755A (ja) 2021-12-09
US20220031742A1 (en) 2022-02-03
US11013765B2 (en) 2021-05-25
US20200237821A1 (en) 2020-07-30
AU2019317229A1 (en) 2021-02-18
EP3835320A1 (en) 2021-06-16
CN113366017A (zh) 2021-09-07
WO2020032784A1 (ko) 2020-02-13
EP3835320A4 (en) 2022-06-01
US11951130B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
MX2021001672A (es) Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CO6230999A2 (es) Anticuerpo anti-esclerostina
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
NZ740221A (en) St2l antagonists and methods of use
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
EA035160B9 (ru) Антитела к st2 и их применение
NZ601617A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
RS54685B1 (en) ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
HRP20211541T1 (hr) Anti-asic1 antitijela i njihove upotrebe
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
MY196874A (en) Humanized anti-basigin antibodies and the use thereof